Patents by Inventor Aseem Ansari
Aseem Ansari has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240124491Abstract: The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a trinucleotide repeat sequence GAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.Type: ApplicationFiled: January 7, 2022Publication date: April 18, 2024Inventors: Aseem ANSARI, Abhijit BHAT, Sean J. JEFFRIES, Pratik SHAH, Chengzhi ZHANG
-
Publication number: 20240100191Abstract: The present technology relates to compositions and methods for modulating expression of genes which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and -B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.Type: ApplicationFiled: July 5, 2023Publication date: March 28, 2024Applicant: Wisconsin Alumni Research FoundationInventors: Aseem Ansari, Graham Erwin, Matthew Grieshop
-
Publication number: 20240050576Abstract: The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CGG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CGG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.Type: ApplicationFiled: October 7, 2022Publication date: February 15, 2024Inventors: Aseem ANSARI, Sean J. JEFFRIES, Pratik SHAH, Chengzhi ZHANG
-
Patent number: 11759533Abstract: The present technology relates to compositions and methods for modulating expression of genes which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and —B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.Type: GrantFiled: March 29, 2018Date of Patent: September 19, 2023Assignee: Wisconsin Alumni Research FoundationInventors: Aseem Ansari, Graham Erwin, Matthew Grieshop
-
Publication number: 20230285573Abstract: The present disclosure relates to compounds and methods for modulating the expression of bean (brain expressed, associated with NEDD4) and treating diseases and conditions in which bean plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence TGGAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence TGGAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.Type: ApplicationFiled: September 26, 2022Publication date: September 14, 2023Inventors: Aseem ANSARI, Pratik SHAH
-
Publication number: 20230285569Abstract: The present disclosure relates to compounds and methods which may be useful for modulating the expression of a target gene comprising a CGG trinucleotide repeat sequence and treating diseases and conditions in which the target gene plays an active role. The present disclosure provides compounds and methods for modulating the expression of fmr1 and fmr2, and provides compounds and methods for treating fragile X syndrome and fragile XE syndrome.Type: ApplicationFiled: January 8, 2021Publication date: September 14, 2023Inventors: Aseem ANSARI, Sean J. JEFFRIES, Pratik SHAH, Chengzhi ZHANG
-
Publication number: 20230241077Abstract: The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and -B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.Type: ApplicationFiled: March 17, 2023Publication date: August 3, 2023Applicant: Wisconsin Alumni Research FoundationInventors: Aseem Ansari, Graham Erwin, Matthew P. Grieshop
-
Publication number: 20230149550Abstract: The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.Type: ApplicationFiled: February 3, 2021Publication date: May 18, 2023Inventors: Aseem ANSARI, Sean J. JEFFRIES, Pratik SHAH, Chengzhi ZHANG
-
Publication number: 20230050819Abstract: The present disclosure relates to compounds and methods which may be useful for modulating the expression of a target gene comprising a CGG trinucleotide repeat sequence and treating diseases and conditions in which the target gene plays an active role. The present disclosure provides compounds and methods for modulating the expression of fmr1 and fmr2, and provides compounds and methods for treating fragile X syndrome and fragile XE syndrome.Type: ApplicationFiled: July 2, 2019Publication date: February 16, 2023Inventors: Aseem ANSARI, Pratik SHAH
-
Publication number: 20210283265Abstract: The present disclosure relates to compounds and methods for modulating the expression of bean (brain expressed, associated with NEDD4) and treating diseases and conditions in which bean plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence TGGAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence TGGAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.Type: ApplicationFiled: April 19, 2019Publication date: September 16, 2021Inventors: Aseem ANSARI, Pratik SHAH
-
Publication number: 20210284629Abstract: The present disclosure relates to compounds and methods for modulating the expression ofc9orf72 (brain expressed, associated with NEDD4) and treating diseases and conditions in which c9orf72 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence GGGGCC; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GGGGCC; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.Type: ApplicationFiled: May 9, 2019Publication date: September 16, 2021Inventors: Aseem ANSARI, Pratik SHAH
-
Publication number: 20210238226Abstract: The present disclosure relates to compounds and methods for modulating the expression of dmpk, atxn1, atxn2, atxn3, cacna1a, atxn7, ppp2r2br tbp, htt, jph3r ar, or atn1 and treating diseases and conditions in which dmpk, atxn1, atxn2, atxn3, cacna1a, atxn1, ppp2r2b, tbp, htt, jph3, ar, or atn1 plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.Type: ApplicationFiled: May 22, 2019Publication date: August 5, 2021Inventors: Aseem ANSARI, Pratik SHAH
-
Publication number: 20210228723Abstract: The present disclosure relates to compounds and methods which may be useful for modulating the expression of fxn and treating diseases and conditions in which fxn plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence GAA; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence GAA; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.Type: ApplicationFiled: May 22, 2019Publication date: July 29, 2021Inventors: Aseem ANSARI, Pratik SHAH
-
Publication number: 20200129522Abstract: The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and —B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.Type: ApplicationFiled: December 11, 2019Publication date: April 30, 2020Inventors: Aseem Ansari, Graham Erwin, Matthew P. Grieshop
-
Patent number: 10517877Abstract: The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and -B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.Type: GrantFiled: March 29, 2017Date of Patent: December 31, 2019Assignee: Wisconsin Alumni Research FoundationInventors: Aseem Ansari, Graham Erwin, Matthew Grieshop
-
Publication number: 20180280541Abstract: The present technology relates to compositions and methods for modulating expression of genes which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and —B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.Type: ApplicationFiled: March 29, 2018Publication date: October 4, 2018Inventors: Aseem Ansari, Graham Erwin, Matthew Grieshop
-
Publication number: 20170281643Abstract: The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and -B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.Type: ApplicationFiled: March 29, 2017Publication date: October 5, 2017Applicant: Wisconsin Alumni Research FoundationInventors: Aseem Ansari, Graham Erwin, Matthew Grieshop
-
Publication number: 20050123936Abstract: A method of evaluating one or more test compounds to identify test compounds that modulate binding of natural or artificial regulatory factors to corresponding single-, double-, or triple-stranded nucleic acid binding sites is described. The method utilizes an isolated nucleic acid target that defines at least one known or putative binding site for a regulatory factor. The nucleic acid target has conjugated or covalently bonded thereto, at a point proximate to, but not within, the binding site: (i) an anchor moiety; (ii) a linker moiety bonded to the anchor moiety; and (iii) a test compound bonded to the linker moiety. To evaluate the test compound, the nucleic acid target of step is then contacted to a reagent mixture comprising one or more natural or artificial regulatory factors specific for the binding site defined in the nucleic acid target.Type: ApplicationFiled: January 16, 2004Publication date: June 9, 2005Inventor: Aseem Ansari